^
Association details:
| Biomarker: | MET underexpression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | TR1801-ADC (DNA replication inhibitor, c-MET-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
TR1801-ADC: a highly potent cMet antibody–drug conjugate with high activity in patient-derived xenograft models of solid tumors
Excerpt:
In vivo xenografts with low–medium cMet expression were also very responsive to TR1801-ADC...Altogether, TR1801-ADC is a new generation cMet ADC with best-in-class preclinical efficacy and good tolerability in rats.
DOI:
https://doi.org/10.1002/1878-0261.12600
